Novo Nordisk A/S (NYSE:NVO) Q1 2024 Earnings Call Transcript
Novo Nordisk A/S misses on earnings expectations. Reported EPS is $0.7 EPS, expectations were $0.77.
Source: insidermonkey.com
Outcomes Trial News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Outcomes Trial. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Outcomes Trial Today - Breaking & Trending Today
Amgen Reports Better-Than-Expected Q1 Results, $50M Milestone Payment - Amgen (NASDAQ:AMGN)
Amgen reported quarterly earnings of $3.96 per share which beat the analyst consensus estimate of $3.87 by 2.33%. The company said EPS decreased by 1% due to higher operating and interest expenses driven by the Horizon acquisition, partially offset by higher revenues.
Source: benzinga.com
FDA Approves Paradise Renal Denervation System: What Comes Next?
(UPDATED) This marks the culmination of more than a decade of work, but there are still questions about where the field goes from here.
Source: tctmd.com
AMGEN PRESENTS LATE-BREAKING PHASE 2 OLPASIRAN DATA AT ESC 2023
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced data from the final analysis of the Phase 2 OCEAN(a)-DOSE study of olpasiran, a small interfering RNA...
Source: prnewswire.com
Esperion Presents Results from New Analysis on Cardiovascular Benefits with Bempedoic Acid Treatment at ENDO 2023
Cardiovascular risk reduction with bempedoic acid shown via the Cholesterol Treatment Trialists’ (CTT) Major Vascular Event endpoint is comparable to the normalized risk reduction with statins observed in the CTT meta-analyses
Source: dicardiology.com